Last reviewed · How we verify

Clorhexidine-Chitosan gel

University of Santiago de Compostela · FDA-approved active Small molecule Quality 2/100

Clorhexidine-Chitosan gel is a Small molecule drug developed by University of Santiago de Compostela. It is currently FDA-approved. Also known as: Bexident Post.

At a glance

Generic nameClorhexidine-Chitosan gel
Also known asBexident Post
SponsorUniversity of Santiago de Compostela
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clorhexidine-Chitosan gel

What is Clorhexidine-Chitosan gel?

Clorhexidine-Chitosan gel is a Small molecule drug developed by University of Santiago de Compostela.

Who makes Clorhexidine-Chitosan gel?

Clorhexidine-Chitosan gel is developed and marketed by University of Santiago de Compostela (see full University of Santiago de Compostela pipeline at /company/university-of-santiago-de-compostela).

Is Clorhexidine-Chitosan gel also known as anything else?

Clorhexidine-Chitosan gel is also known as Bexident Post.

What development phase is Clorhexidine-Chitosan gel in?

Clorhexidine-Chitosan gel is FDA-approved (marketed).

Related